Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,450.00
0.00 (0.00%)
At close: Jun 5, 2025, 3:30 PM KST

Kyongbo Pharmaceutical Revenue

Kyongbo Pharmaceutical had revenue of 60.59B KRW in the quarter ending March 31, 2025, a decrease of -3.21%. This brings the company's revenue in the last twelve months to 236.54B, up 2.40% year-over-year. In the year 2024, Kyongbo Pharmaceutical had annual revenue of 238.56B with 10.26% growth.

Revenue (ttm)
236.54B
Revenue Growth
+2.40%
P/S Ratio
0.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
130.29B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024238.56B22.20B10.26%
Dec 31, 2023216.36B20.09B10.24%
Dec 31, 2022196.26B25.61B15.00%
Dec 31, 2021170.66B-44.63B-20.73%
Dec 31, 2020215.29B23.58B12.30%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,898.69B
Celltrion 3,662.23B
ALTEOGEN 151.65B
Yuhan 2,114.76B
SK Biopharmaceuticals 578.00B
HLB Co., Ltd. 74.64B
PharmaResearch 392.31B
LigaChem Biosciences 146.42B
Revenue Rankings